Molecular mechanisms of resistance to anti-programmed cell death 1 (PD-1) therapy in melanoma
Year: 2025
Type: article
Abstract: Background: Immune checkpoint inhibitors (ICIs) targeting programmed cell death 1 (PD-1) have transformed the treatment landscape of melanoma, but responses remain highly variable. Identifying molecular factors that influence therapeutic outcomes can provide insights for improving the efficacy of PD-1-based therapies. This study aimed to examine the differential expression of immune-related genes and identify molecular signatures associated with resistance to anti-PD-1 therapy in melanoma patients.
Source: EJC Skin Cancer
Authors: B. Sorroche, R. Teixeira, V. de Souza, I. Tosi, V. Paes, T. Araujo, A.C. Laus, V. Vazquez
Institution: Hospital de Câncer de Barretos
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,340
OpenAlex ID: W4409145145